Release Details

Taysha Gene Therapies to Participate in JMP Securities Hematology and Oncology Summit

11-29-2022   |  

DALLAS, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will participate in the JMP Securities Hematology and Oncology Summit, which is taking place virtually from Tuesday, December 6, 2022, through Wednesday, December 7, 2022. Taysha’s President, Founder and Chief Executive Officer, RA Session II, will participate in a fire side chat with Silvan Turkan, Ph.D., Senior Research Analyst at JMP Securities, at 3:40 PM ET on Wednesday, December 7, 2022.

A webcast of the fire side chat will be available in the “Events & Media” section of the Taysha corporate website at An archived version of the webcast will be available on the website for 90 days.

About Taysha Gene Therapies        

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at

Company Contact:
Kimberly Lee, D.O.
Chief Corporate Affairs Officer
Taysha Gene Therapies

Media Contact:
Carolyn Hawley
Evoke Canale

Primary Logo

Source: Taysha Gene Therapies, Inc.

Scroll to top